Respiratory Disease Vaccines Market Research Report 2025: Analysis and Forecast (2020-2030) Featuring GSK, Johnson & Johnson Services, Pfizer, Sanofi, Serum Institute of India, SINOVAC Biotech & More
Respiratory Disease Vaccine Market
Dublin, Feb. 06, 2025 (GLOBE NEWSWIRE) -- The "Respiratory Disease Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to ResearchAndMarkets.com's offering.The Respiratory Disease Vaccine Market was valued at USD 94.60 billion in 2024, and is expected to reach USD 101.56 billion by 2030, rising at a CAGR of 1.15%.
The global aging population is at a higher risk of respiratory diseases. As the elderly population grows, there is a greater need for vaccines to protect this vulnerable group. Government and healthcare organizations worldwide recommend or mandate vaccinations for certain respiratory diseases, such as influenza. These recommendations drive vaccine adoption and coverage rates. The emergence of new respiratory viruses, as witnessed during the COVID-19 pandemic, highlights the importance of preparedness through vaccination.Governments and organizations invest in vaccines as a key part of pandemic response plans. Public health campaigns and initiatives promote vaccination and raise awareness about the benefits of respiratory disease vaccines. These efforts aim to increase vaccine uptake. International organizations like the World Health Organization (WHO) and UNICEF work to expand vaccination access in low- and middle-income countries. Global immunization programs aim to reduce the burden of respiratory diseases.Key Market Drivers
Increasing Prevalence of Respiratory Diseases
Rising Aging Population
Vaccine Mandates and Recommendations
Global Immunization Programs
Key Market Challenges
Vaccine Hesitancy and Misinformation
Supply Chain Disruptions
Key Market Trends
Pneumococcal Vaccines
Asia Pacific held the largest market share in the Global Respiratory Disease Vaccine Market in 2024. The Asia Pacific region is home to a substantial portion of the world's population, including densely populated countries like China and India. The sheer number of people in the region creates a significant market for respiratory disease vaccines. Many countries in the Asia Pacific have been experiencing economic growth, leading to increased healthcare spending. This has allowed for greater investment in healthcare infrastructure, including vaccination programs.Awareness about the importance of vaccination has been on the rise in the Asia Pacific region. Governments and healthcare organizations have been actively promoting immunization, including respiratory disease vaccines, to combat the burden of preventable diseases. Like many other regions, the Asia Pacific is experiencing demographic changes with a growing aging population. Older adults are more susceptible to respiratory diseases, such as influenza and pneumonia, driving the demand for vaccines.Key Market Players
GSK PLC
Johnson & Johnson Services, Inc.
Pfizer Inc.
Sanofi SA
Serum Institute of India Pvt. Ltd.
SINOVAC Biotech Ltd.
Bavarian Nordic A/S
Merck & Co. Inc.
AstraZeneca PLC
Report ScopeIn this report, the Global Respiratory Disease Vaccine Market has been segmented into the following categories:By Type
Viral Vaccine
Bacterial Vaccine
Combination Vaccine
By Infection
COVID-19
Influenza
Respiratory Syncytial Virus (RSV)
Pneumonia
Others
By Distribution Channel
Hospital & Retail Pharmacies
Government Suppliers
Others
By Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
South Korea
Australia
Japan
Europe
Germany
France
United Kingdom
Spain
Italy
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Key Attributes
Report Attribute
Details
No. of Pages
180
Forecast Period
2024-2030
Estimated Market Value (USD) in 2024
$94.6 Billion
Forecasted Market Value (USD) by 2030
$101.56 Billion
Compound Annual Growth Rate
1.1%
Regions Covered
Global
For more information about this report visit https://www.researchandmarkets.com/r/yfsvaz
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
Respiratory Disease Vaccine Market
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
33 minutes ago
- Yahoo
Dangerous hidden side effect of Covid infection revealed by new study
Covid may prematurely age blood vessels by around five years, according to a new study, increasing the risk of heart attack and stroke. Research published in the European Heart Journal revealed that a Covid infection could accelerate the ageing of blood vessels, particularly in women. Vaccinated individuals show less stiffening in their arteries and stabilised symptoms over time in comparison to those who had not been protected against Covid. Lead researcher Professor Rosa Maria Bruno, from Université Paris Cité, said: "We know that Covid can directly affect blood vessels. We believe that this may result in what we call early vascular ageing, meaning that your blood vessels are older than your chronological age and you are more susceptible to heart disease. 'If that is happening, we need to identify who is at risk at an early stage to prevent heart attacks and strokes." The new study tested nearly 2,500 people from across the world, categorising them based on whether they had Covid and whether they had been hospitalised for it, both in a general ward and in an intensive care unit. Tests were taken six months after an infection and again after 12 months. It measured each person's vascular age with a device that examines how quickly a wave of blood pressure travels between the artery in the neck and the legs. The higher the measurement meant the stiffer the blood vessels, indicating a higher vascular age. It found that all three groups of patients who had a Covid infection had stiffer arteries compared to those who hadn't been affected. The average increase in women was 0.55 meters per second for those who had mild Covid, 0.60 for those who had been hospitalised, and 1.09 for those in intensive care. According to researchers, an increase of around 0.5 meters per second is "clinically relevant" and equivalent to ageing around five years. It also increases the risk of cardiovascular disease, like heart attack, stroke or sudden cardiac arrest, in 60-year-old women by 3 per cent. The difference between men and women could come down to immune systems, Prof Bruno added. She said: 'Women mount a more rapid and robust immune response, which can protect them from infection. However, this same response can also increase damage to blood vessels after the initial infection.' She said the virus acts on specific receptors in the body that are in the lining of the blood vessels. The virus will use these receptors to enter and infect cells. Last month, it was reported that a new strain of Covid had spread across the UK, accounting for the highest proportion of cases - around 30 per cent. Experts warned the Stratus strain was resisting immunity and had a unique symptom of giving people a hoarse voice.
Yahoo
3 hours ago
- Yahoo
The Wistar Institute Receives $17 Million NIH Grant for Personalized HIV Cure Research
Philadelphia-led consortium is selected to tailor HIV curative strategies to participant Philadelphia, PA, Aug. 19, 2025 (GLOBE NEWSWIRE) -- The Wistar Institute announces the National Institutes of Health (NIH) granted a five-year, $17 million research award to launch iCure Consortium to develop individualized 'cure regimens' for HIV. The Wistar-led, iCure Consortium's objective is to advance strategies to cure HIV through tailored personalized medicine. 'Today 38 million people still live with HIV worldwide, and 1.3 million contract the virus each year,' said Luis J. Montaner, D.V.M., iCure principal investigator, executive vice president of The Wistar Institute and director of Wistar's HIV Cure and Viral Diseases Center. 'For the first time, this grant brings our best team together working towards a cure tailored to each participant by pairing the latest in neutralizing antibody and cell-therapy breakthroughs against the unique, person-specific features of HIV.' iCure Consortium will test a six-part, individually-tailored therapy designed to wipe out the persistent viral reservoir that remains after antiretroviral therapy in an effort to deliver durable, drug-free remission. The project combines six advanced tactics—neutralizing antibodies, mRNA therapy, viral binders, engineered CAR-T and 'Natural Killer' (NK) cells, and precision latency 'wake-up' drugs—all designed against each patient's unique virus. 'Ending HIV demands more than management—it demands eradication,' said Drew Weissman, M.D., Ph.D., iCure co‑principal investigator, 2023 Nobel Laureate and Roberts Family Professor in Vaccine Research at the Perelman School of Medicine at the University of Pennsylvania. 'This project now allows us to apply our breakthroughs in RNA therapy as part of a cure-directed strategy.' How iCure Works• Wake the latent virus• Map and target unique weak spots with tailored antibodies• Destroy infected cells using 'super‑charged' CAR‑T and NK cells• Enhance clearance and block relapse with bispecific binders In the first step, researchers reactivate the virus in a sample of the participant's blood and identify mutations that the participant has not yet developed antibodies against. They then develop a tailored antibody therapy cocktail specifically designed against these specific mutations. In the next stage, researchers focus on preventing HIV from returning. To do this, they develop person-specific antibodies or small molecule binders that can act as 'homing devices' — beacons that can lead immune cells to the latent virus. Then they genetically modify CAR-T cells and NK cells (immune cells that destroy viruses) to express or use these homing devices to better clear infected cells. Finally, researchers further enhance NK cells. First, they develop stronger and more durable cells, called adaptive NK cells, by supercharging their virus-killing ability. Then, they deploy small-molecule drugs called bispecifics, which bind NK cells to the infected cells they are targeting. "iCure takes full advantage of the advances made in understanding how and where HIV hides from the immune system," said Montaner. "We've built on our knowledge and can use that information to identify a first of its kind targeting to a person's unique HIV features." iCure furthers the research groundwork laid by the BEAT-HIV Martin Delaney Collaboratory ( a Philadelphia-based consortium of more than 95 leading HIV researchers co-led by Dr. Montaner. Montaner called the NIH grant a 'once in a lifetime opportunity' that reflects Wistar's track record as a scientific leader in the effort to develop an HIV cure, as well as its grassroots support and collaboration with the HIV community. 'By the end of this study we hope to have a process by which to identify the virus that we need to go after in each person and have a basis to design clinical trials choosing the best of these strategies to move forward,' said Montaner. Other institutions participating in this study include Johns Hopkins Medicine and iCure co-principal investigator Robert Siliciano, M.D., Ph.D., the University of Pennsylvania, Philadelphia FIGHT, the Ragon Institute at Harvard University, George Washington University, Duke University, and Massachusetts Institute of Technology. The iCure program is funded by the National Institute of Allergy and Infectious Diseases, part of NIH, under award number UM1AI191272. ### The Wistar Institute is an international leader in biomedical research with special expertise in cancer research and vaccine development. Founded in 1892 as the first independent nonprofit biomedical research institute in the United States, Wistar has held the prestigious Cancer Center designation from the National Cancer Institute since 1972. The Institute works actively to ensure that research advances move from the laboratory to the clinic as quickly as possible. CONTACT: Darien Sutton The Wistar Institute 215-870-2048 dsutton@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Boston Globe
3 hours ago
- Boston Globe
A debilitating mosquito-borne virus spreads to more regions of the world
The World Health Organization is warning that current transmission patterns resemble a global outbreak that infected 500,000 people 20 years ago, contributing to a surge of new disabilities. Advertisement Although it is rarely fatal, chikungunya causes excruciating and prolonged joint pain and weakness. 'You have people who were working, with no disabilities, and from one day to the next, they cannot even type on a phone, they can't hold a pen, a woman cannot even hold a knife to be able to cook for her family,' said Dr. Diana Rojas Alvarez, who leads chikungunya work at the WHO. 'It really impacts quality of life and also the economy of the country.' A worker sprayed insecticide to prevent the spread of Chikungunya in Guangdong Province, China, on Aug. 3. VCG/Getty Images What is chikungunya, and how dangerous is it? Like Zika and dengue fever, chikungunya is an RNA virus transmitted by mosquitoes. Two different species of mosquitoes, Aedes aegypti and Aedes albopictus, transmit chikungunya. Between four and eight days after a bite, a person can develop symptoms including fever, joint pain and a rash. Advertisement Unlike dengue and Zika infections, the majority of which are asymptomatic, chikungunya sickens most people it infects. In rare instances, chikungunya can kill young children and older adults. 'Fatality levels are low, but we really care about chikungunya because it leaves people with months or potentially years of debilitating pain,' said Scott Weaver, an expert and the scientific director of the Galveston National Laboratory in Texas. He added: 'That has not only an individual toll but also a social one, with strain on health care systems, economic impact, the demand on caregivers, a lot of things.' Chikungunya is often misdiagnosed as dengue, which causes the same symptoms at first. Dengue symptoms usually clear up in a week or two; chikungunya symptoms become chronic in as many as 40% of people infected, with debilitating joint pain lasting for months or years. Between 2005 and 2007, more than two-thirds of all the disabilities -- including those caused by cancer, arthritis and diabetes -- reported in India were the result of a chikungunya outbreak that was sweeping through the country. A vaccination against on La Reunion on April 7. RICHARD BOUHET/AFP via Getty Images Who is at risk? By the end of 2024, transmission of the virus had been reported in 199 countries, on every continent except Antarctica. The WHO estimates that 5.6 billion people live in areas where the mosquitoes that transmit the virus can live. These mosquitoes are daytime biters, feeding on people who are at work, at school or on a bus. Climate change is driving the spread of chikungunya-carrying mosquitoes in two ways. A warmer, wetter world provides more suitable habitat. And extreme weather events can cause more breeding in floods -- or displace people, who cluster in areas with poor water and sanitation supply. Advertisement The Aedes albopictus mosquito has markedly expanded its presence in Europe in recent years: The insect has been found in Amsterdam and Geneva. In South America, Aedes aegypti carries the virus and thrives in low-income neighborhoods in rapidly growing cities with patchy water systems. 'In the U.S. I don't think we're going to see massive outbreaks of chikungunya' because people in warm areas use air conditioning and spend a lot of time indoors, Weaver said. 'But in places like China and the Southern Cone of South America, the warming temperatures are going to have a big impact because people don't stay inside with air conditioners in their houses or their workplaces. They don't even like to screen their windows in many parts of Asia and South America.' People seem to become immune to chikungunya after an infection and so, if it sweeps through an area, it can be a couple of decades before there are enough immunologically vulnerable people to sustain another outbreak. But in places such as India and Brazil, populations are so large that the virus is circulating constantly. Many countries in Africa that did not have circulating chikungunya, such as Chad and Mali, have reported cases in the past few years. Residents walked past a sign urging mosquito control in Guangzhou, China, on Aug. 6, 2025. The message reads, "Let's work together to clear stagnant water and eliminate mosquito breeding". Uncredited/Associated Press Is there a vaccine? There are two vaccines for chikungunya, but they are produced in limited quantities for use mainly by travelers from industrialized countries. The newest vaccine, made by Bavarian Nordic, sells for about $270 per shot in the United States, a price well beyond the reach of a country such as Paraguay, which has had huge chikungunya outbreaks and would ideally vaccinate much of the population. Brazil's Butantan Institute is working on making a lower-cost version of another vaccine. Advertisement Neither vaccine currently has the kind of WHO recommendation that might lead to accelerated development of an affordable product. Doing a clinical trial of the kind the agency requires is difficult: Chikungunya outbreaks happen so fast that they're over before the research can begin. Rojas said the WHO's vaccine committee was reviewing chikungunya outbreak data to consider options for a possible recommendation. What else can be done? The best protection against chikungunya is not to get bitten. The next step is to reduce mosquito breeding sites. In China, public health officials are going house to house to look for stagnant water. Surveillance for chikungunya is still weak. Rojas said the WHO was trying to untangle how much of the current surge was new cases and how much was transmission that was already occurring but poorly tracked or reported. There is a molecular diagnostic test that screens for Zika, dengue and chikungunya at the same time, but more countries need to adopt it. Disease surveillance globally has been weakened by the abrupt cuts in funding from the U.S. government, which was supporting much of this work in low-income countries. Is this a new virus? Chikungunya was first identified in Tanzania in the 1950s, and caused sporadic outbreaks in Africa and Asia in the next decades. But the virus didn't attract much attention from public health specialists until 2004. That year, an outbreak in Kenya spread to La Réunion, a French territory in the Indian Ocean. There, chikungunya raged through the population: One-third of the people on the island were infected. Advertisement That same strain of the virus made its way to South Asia, and caused huge outbreaks in India from 2005 to 2007. And from there travelers took chikungunya around the world. By late 2013, the virus had made its way to the Caribbean and once again began to tear through a population that lacked immunity. There were 1.8 million reported infections in the region by the end of 2015. Chikungunya then made its way down through South America -- and a new strain from Angola was introduced to Brazil at the same time -- and the two have been circulating since then. Chikungunya cases in South America have risen steadily since 2023, alongside a surge in dengue cases. This article originally appeared in
